NYSE: NVO DEADLINE REMINDER: Berger Montague Reminds Nordisk A/S (NYSE: NVO) Investors of Important Class Action Lawsuit Deadline

Core Viewpoint - Berger Montague PC is investigating potential securities fraud claims against Novo Nordisk A/S following a securities class action lawsuit filed on behalf of investors who acquired Novo securities during the Class Period from May 7, 2025, to July 28, 2025 [1][3] Group 1 - The lawsuit alleges that Novo Nordisk made false and misleading statements regarding the impact of compounded GLP-1 drugs, specifically underestimating the effect of the FDA's personalization exception [3] - The company allegedly overstated the likelihood that patients would switch to its branded drugs, such as Ozempic® and Wegovy®, leading to significant investor losses [3] - Investors who purchased Novo securities during the Class Period have until September 30, 2025, to seek appointment as lead plaintiff representative of the class [2]